Roivant Sciences (ROIV) Insider Manchester Sells $7.1M of Stock
Keith Manchester sold his shares as Roivant Sciences' stock trades below recent highs.
Reviewed by automated data checks against the source filing. How we make and check alerts
Keith Manchester sold 200,000 shares of Roivant Sciences Ltd. ($ROIV) at an average price of $35.45, worth about $7.09 million, on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ROIV is up 2.6% after 1 week, down 2.5% after 1 month and down 5.3% to date (from the $35.39 close on Jun 30, 2026).
ROIV
Roivant Sciences Ltd.
Key Points
- Keith Manchester sold 200,000 shares of Roivant Sciences Ltd. (ROIV) for about $7.09 million on June 30, 2026, with shares trading at $35.39.
- The company's stock is currently down from a 52-week high of $42.50, reflecting recent market fluctuations.
- Analysts maintain a 'Buy' rating, with targets ranging from $46 to $55, suggesting confidence in Roivant's potential despite recent insider sales.
Get $ROIV trade alerts by text
We text you when insiders, Congress or big funds trade $ROIV. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Roivant Sciences Ltd. alert may contain errors. Disclosures
Insider Buying and Selling at Roivant Sciences Ltd.
Keith Manchester sold 200,000 shares of Roivant Sciences Ltd. (NasdaqGS: ROIV) on June 30, 2026, for about $7.09 million. The shares were sold at a price of $35.45, while the stock traded at $35.39 on the day of publication.
Recent Sales by Other Insiders
This transaction is part of a series of insider trades at Roivant Sciences. On the same day, Qvt Financial LP and Gold Daniel Allen each sold 12,380 shares, valued at $436,766. Additionally, Mayukh Sukhatme, the company's President & CIO, executed two trades on June 25, selling 500,000 shares for $17.07 million after exercising stock options. Another insider, Eric Venker, also sold 200,000 shares on June 24 for a total value of $6.63 million. These sales indicate significant movements among the company's leadership, which may signal a strategic shift or respond to market conditions.
How Roivant Sciences Ltd. Stock Has Traded
Currently, Roivant Sciences' stock is trading at $35.39, down from its 52-week high of $42.50. The stock's recent performance shows a significant dip compared to its highs, which could reflect broader market trends or company-specific challenges. With a recent average price around $36.26, the stock is below its 50-day moving average.
Analysts Set New Price Targets
Analysts are generally optimistic about Roivant Sciences. On September 17, 2026, Stifel initiated coverage with a 'Buy' rating and a target of $51. TD Cowen also maintains a 'Buy' rating with a target of $55. Guggenheim and HC Wainwright have similarly positive outlooks, with targets of $46 and $47, respectively. The consensus recommendation for the stock remains strong, indicating confidence in Roivant’s growth potential.
What Roivant Sciences Ltd. Does
Roivant Sciences Ltd., based in London, is a biopharmaceutical company focused on developing and commercializing medicines and technologies. The company has several clinical candidates addressing various autoimmune and chronic diseases, which positions it well within the biotechnology sector. Recent insider trades by management suggest strategic adjustments as the company navigates its growth path.
What's Next for Roivant
Looking ahead, investors will be watching for the company's next earnings report on November 9, 2026. The recent insider activities and analyst ratings may influence market sentiment in the lead-up to this event. As always, it’s important to remember that insider transactions reflect past actions and may not represent current positions.
Related Filing Alerts
Source: Keith Manchester's Form 4 filing on $ROIV (Jun 30, 2026). Find the original filing: ROIV Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts